Recruitment has not yet been initiated

The goal of this study is to determine the utility of cerebrospinal fluid (CSF) cell-free DNA (cfDNA) as a prognostic biomarker in glioblastoma (GBM).

Inclusion Criteria:

Cohort A

• Participants must be able to understand and be willing to sign a written informed consent document
• Age ≥ 18 years
• MRI with contrast-enhancing lesion concerning for high-grade glioma in absence of known systemic malignancy
• Clinical consensus of presumed diagnosis of high grade glioma between (1) neuroradiology (2) neurosurgery; and (3) principal investigator
• No prior tumor directed therapy
• Planned radiation therapy for glioblastoma
• Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
• Patients must be willing to consent to MSK IRB#12-245

Cohort B

• Participants must be able to understand and be willing to sign a written informed consent document
• Age ≥ 18 years
• Histologic confirmed glioblastoma (WHO grade IV), IDH wild type per IHC
• No prior tumor-directed therapies except surgical resection or biopsy
• Patients who have gliadel wafers placed during upfront surgery are excluded
• Planned radiation therapy for glioblastoma
• Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
• Patients must be willing to consent to MSK IRB#12-245

Exclusion Criteria:

Cohorts A and B

• Any case for which there is a medical contraindication or safety concern regarding a lumbar puncture under standard medical guidelines at MSK
• Refusal to undergo serial lumbar punctures

• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.